Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Identifying specific chemotherapeutic agents in Medicare data: a validation study.

Lund JL, Stürmer T, Harlan LC, Sanoff HK, Sandler RS, Brookhart MA, Warren JL.

Med Care. 2013 May;51(5):e27-34. doi: 10.1097/MLR.0b013e31823ab60f.

2.

Utility of the SEER-Medicare data to identify chemotherapy use.

Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB.

Med Care. 2002 Aug;40(8 Suppl):IV-55-61.

PMID:
12187169
3.

Construct validity of medicare chemotherapy claims: the case of 5FU.

Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA.

Med Care. 2002 Mar;40(3):201-11.

PMID:
11880793
4.

Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.

Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI.

J Natl Cancer Inst. 2009 Dec 2;101(23):1633-41. doi: 10.1093/jnci/djp387. Epub 2009 Nov 10. Erratum in: J Natl Cancer Inst. 2010 Feb 24;102(4):282-3.

5.

Validation of electronic data on chemotherapy and hormone therapy use in HMOs.

Ritzwoller DP, Carroll N, Delate T, O'Keeffe-Rossetti M, Fishman PA, Loggers ET, Aiello Bowles EJ, Elston-Lafata J, Hornbrook MC.

Med Care. 2013 Oct;51(10):e67-73. doi: 10.1097/MLR.0b013e31824def85.

6.

Accuracy of Medicare claims data for estimation of cancer incidence and resection rates among elderly Americans.

Whittle J, Steinberg EP, Anderson GF, Herbert R.

Med Care. 1991 Dec;29(12):1226-36.

PMID:
1745080
7.

Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage.

Chawla N, Yabroff KR, Mariotto A, McNeel TS, Schrag D, Warren JL.

Ann Epidemiol. 2014 Sep;24(9):666-72, 672.e1-2. doi: 10.1016/j.annepidem.2014.06.099. Epub 2014 Jul 3.

8.

Comparison of SEER Treatment Data With Medicare Claims.

Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, Warren JL.

Med Care. 2016 Sep;54(9):e55-64. doi: 10.1097/MLR.0000000000000073.

9.

Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study.

Fleming ST, Kimmick GG, Sabatino SA, Cress RD, Wu XC, Trentham-Dietz A, Huang B, Hwang W, Liff JM; Patterns of Care Study Group.

Ann Epidemiol. 2012 Nov;22(11):807-13. doi: 10.1016/j.annepidem.2012.08.001. Epub 2012 Sep 1.

PMID:
22948184
10.

Linking physician characteristics and medicare claims data: issues in data availability, quality, and measurement.

Baldwin LM, Adamache W, Klabunde CN, Kenward K, Dahlman C, L Warren J.

Med Care. 2002 Aug;40(8 Suppl):IV-82-95.

PMID:
12187173
11.

Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer.

Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM.

Am J Gastroenterol. 2006 Oct;101(10):2308-18.

PMID:
17032196
12.
13.

Insurance status and the use of guideline therapy in the treatment of selected cancers.

Harlan LC, Greene AL, Clegg LX, Mooney M, Stevens JL, Brown ML.

J Clin Oncol. 2005 Dec 20;23(36):9079-88. Epub 2005 Nov 21.

PMID:
16301598
14.

Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States.

Warren JL, Harlan LC, Stevens J, Little RF, Abel GA.

J Clin Oncol. 2013 Jun 1;31(16):1984-9. doi: 10.1200/JCO.2012.46.3323. Epub 2013 Apr 8.

15.

Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.

Meyers J, Yu Y, Kaye JA, Davis KL.

Appl Health Econ Health Policy. 2013 Jun;11(3):275-86. doi: 10.1007/s40258-013-0032-2.

PMID:
23677706
16.

Provider Differences in Use of Implanted Ports in Older Adults With Cancer.

Lipitz-Snyderman A, Elkin EB, Atoria CL, Sima CS, Epstein AS, Blinder V, Sepkowitz KA, Bach PB.

Med Care. 2015 Jul;53(7):646-52. doi: 10.1097/MLR.0000000000000368.

17.

Sensitivity of Medicare claims data for measuring use of standard multiagent chemotherapy regimens.

Lamont EB, Lan L.

Med Care. 2014 Mar;52(3):e15-20. doi: 10.1097/MLR.0b013e31824e342f.

18.

Information gained from linking SEER Cancer Registry Data to state-level hospital discharge abstracts. Surveillance, Epidemiology, and End Results.

Brooks JM, Chrischilles E, Scott S, Ritho J, Chen-Hardee S.

Med Care. 2000 Nov;38(11):1131-40.

PMID:
11078053
19.

Does reimbursement influence chemotherapy treatment for cancer patients?

Jacobson M, O'Malley AJ, Earle CC, Pakes J, Gaccione P, Newhouse JP.

Health Aff (Millwood). 2006 Mar-Apr;25(2):437-43.

PMID:
16522584
20.

Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane, and capecitabine: a descriptive report.

Donato BM, Burns L, Willey V, Cohenuram M, Oliveria S, Yood MU.

Clin Ther. 2010 Mar;32(3):546-54. doi: 10.1016/j.clinthera.2010.03.007.

PMID:
20399992

Supplemental Content

Support Center